首页> 外文期刊>Retina >The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes.
【24h】

The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes.

机译:苯肾上腺素2.5%与苯肾上腺素10%对糖尿病患者瞳孔扩张的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. METHODS: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. RESULTS: There was no statistically significant difference in the amount of pupillary dilation between the three groups. CONCLUSION: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.
机译:目的:进行了一项前瞻性,双盲研究,比较了1%托吡卡胺和2.5%苯肾上腺素与1%托卡酰胺和10%苯肾上腺素的组合对糖尿病患者瞳孔扩张的临床疗效。方法:连续向127例糖尿病患者中,一只眼睛2.5%的去氧肾上腺素,另一只眼睛的10%的去氧肾上腺素,两只眼睛的2.5%的去氧肾上腺素,或两只眼睛的10%的去氧肾上腺素,均被给予糖尿病患者。所有患者双眼均接受1%的托吡卡胺。结果:三组之间的瞳孔扩张量没有统计学上的显着差异。结论:由于2.5%的去氧肾上腺素可能比10%的浓度产生更低的副作用,因此我们建议使用较低的浓度,尤其是在已经表现出较高的血管疾病和自主神经功能障碍的糖尿病患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号